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ENGLISH SUMMARY 
Chronic pancreatitis (CP) is a fibro-inflammatory disease with progressive, 
irreversible damage to the glandular tissue, in time leading to endocrine and exocrine 
insufficiency. Many CP patients are affected by chronic abdominal pain. Assessment 
of pancreatic pain is typically based on non-validated questionnaires or questionnaires 
developed for other types of chronic pain. Research suggests that a detailed 
characterization of pain can lead to mechanism-based treatment algorithms, but 
thorough groundwork must be performed in order for the algorithm to be able to work 
sufficiently. 
This thesis is a collection of a narrative review and three original manuscripts, based 
on four studies. It provides the basis for characterizing pancreatic pain in a detailed 
manner, focusing on pain mechanisms and risk factors for pancreatic pain.  
The narrative review provides the background for estimating pain as objectively as 
possible and as detailed as possible. In manuscript 2, we assessed pain prevalence in 
a cohort of CP patients and detected associated risk factors for pancreatic pain. In 
manuscript 3, the sensory function in patients with CP was assessed through 
quantitative sensory testing. Manuscript 4 concerned the development of a validated, 
reliable, feasible short form of a pain questionnaire developed explicitly for CP 
patients. 
The narrative review provides a theory of mechanism-based treatment algorithms as 
a more individual-oriented way of treating pain that could gain ground over the next 
decade. 
In manuscript 2, we concluded that pancreatic pain was present in almost 60% of CP 
patients, and most had intermittent pain. Risk factors for pain included very heavy 
alcohol abuse, cigarette smoking, exocrine insufficiency, pancreatic duct changes, 
pseudocysts, and duodenal stenosis. 
In manuscript 3, we showed that patients with painful CP had different pain processing 
than healthy volunteers and that specific defective pain mechanisms, especially 
conditioned pain modulation (CPM), were related to clinical pain intensity.  
The final short form from manuscript 4 consisted of five pain dimensions, comprising 
six questions. Three types of validity were investigated, including content validity, 
construct validity, and criterion validity. The short form was hereafter shown to be 
reliable.  
In conclusion, the studies have contributed with new knowledge about pancreatic pain 
and have developed an instrument to assess the pain in a valid and reliable way. This 
PAIN IN PATIENTS WITH CHRONIC PANCREATITIS 
10 




Kronisk pancreatitis (CP) er en fibro-inflammatorisk sygdom med progressiv, 
irreversibel skade på bugspytkirtelvævet. Med tiden kan det føre til endokrin og 
eksokrin insufficiens. Mange CP-patienter lider af kroniske mavesmerter. Smerterne 
fra bugspytkirtlen bliver typisk vurderet ud fra ikke-validerede spørgeskemaer eller 
spørgeskemaer som er udviklet til andre typer af kroniske smerter. Forskning tyder 
på, at en detaljeret karakterisering af smerte kan føre til mekanismebaserede 
behandlingsalgoritmer. For at en sådan behandlingsalgoritme kan fungere, så kræver 
det dog at forarbejdet med smertekarakteriseringen er grundigt gennemarbejdet. 
Denne afhandling er en samling af et narrativt review og tre originale manuskripter, 
der er baseret på fire undersøgelser. Sammen danner grundlaget for karakterisering af 
smerter i bugspytkirtlen på en detaljeret måde med fokus på smertemekanismer og 
risikofaktorer for smerter. 
Det narrative review gennemgår baggrunden for at estimere smerte så objektivt og 
detaljeret som muligt. I manuskript 2 undersøgte vi prævalensen af smerte i en gruppe 
CP-patienter samt mulige risikofaktorer for smerter ved CP. I manuskript 3 
undersøgte vi den sensoriske funktion ved patienter med CP gennem kvantitativ 
sensorisk testning. Manuskript 4 omhandlede udviklingen af en valideret, pålidelig og 
gennemførlig kort udgave af smerte-spørgeskemaet COMPAT, der blev udviklet 
eksplicit til CP-patienter. 
Den narrative gennemgang producerede en teori om mekanismebaserede 
behandlingsalgoritmer som en mere individ orienteret måde at behandle smerter på. 
Denne metode har potentiale til at kunne vinde indpas over de kommende år. 
I manuskript 2 konkluderede vi, at bugspytkirtelsmerter var til stede hos næsten 60% 
af CP-patienterne, og de fleste havde intermitterende smerter. Risikofaktorer for 
smerte omfattede meget stort alkoholmisbrug, rygning, eksokrin insufficiens, 
ændringer i bugspytkirtel-udførselsgangenes anatomi, pseudocyster og duodenal 
stenose. 
I manuskript 3 viste vi, at centrale smertemekanismer var ændret ved patienter med 
smertefuld CP sammenlignet med raske frivillige, og at specifikke defekte 
smertemekanismer, især betinget smertemodulation (CPM), var relateret til klinisk 
smerteintensitet. 
Den endelige korte udgave af COMPAT spørgeskemaet fra manuskript 4 bestod af 
fem smertedimensioner, der indeholdt i alt seks spørgsmål. Tre typer validitet blev 
undersøgt, herunder i forhold til indhold, konstruktion og kriterier. Til sidst viste vi at 
den korte udgave af COMPAT var pålidelig. 
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Afslutningsvis har undersøgelserne bidraget med ny viden om smerter i 
bugspytkirtlen og har udviklet et instrument til at vurdere smerten på en valid og 
pålidelig måde. Dette kan bruges i forskning og klinisk praksis for at forbedre plejen 
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CHAPTER 1. INTRODUCTION 
Pain is a frequent symptom in the primary and secondary health systems, and chronic 
pain affects up to 20% of the adult population1,2. Chronic pain has significant 
consequences on patients' quality of life as it affects physical and psychological 
health3,4, daily activities5, employment6, and economic well-being, including 
employment7. 
Chronic pain is defined as pain outlasting standard healing time for the specific tissue; 
usually, this is considered when pain persists beyond 3-6 months8,9. Pain severity is 
not necessarily correlated with the amount of tissue damage, and symptoms can 
persevere long beyond the resolution of the damage10. Cognitive factors as, e.g., 
coping style11, previous experiences with pain12, emotional factors13, education11, and 
the pain-associated reactions of the patient's close acquaintances10 can affect the 
patient's perceived pain severity. 
Chronic pain has significant direct and indirect associated societal costs. These are 
exemplified by a chronic pain-associated estimated annual cost of $210 billion in the 
United States of America10. Pain treatment is an essential part of this equation's 
solution, as optimized pain treatment can, besides enhancing the quality of life in 
patients, lower chronic pain costs. The cost is lowered by minimizing admissions due 
to pain, reducing the need for disability payments, and diminished productivity7,10. 
Pain treatment remains challenging due to several factors. These factors include 
different condition-associated complications that can worsen chronic pain, the many 
pain associated risk factors, the diversity of possibly affected pain mechanisms, many 
different origins of pain, and pharmacological treatments with a broad spectrum of 
side effects14. 
To improve pain treatment, a step must be taken from treating pain patients as a 
homogenous group to targeting intervention according to 1) affected pain 
mechanisms15, 2) pain qualities16, and 3) cognitive factors such as e.g., coping style 
and psychological profiles17–20. In this context, pain characterization regarding risk 
factors, pain severity, pain quality, psychological handling, and neurophysiological 
examinations of pain mechanisms are essential.  
Objectively estimating pain intensity is impossible due to the subjective nature of pain 
sensation21. The gold standard for assessing pain intensity is by patient self-report. 
Many different scales exist, such as the Visual Analogue Scale (VAS), the Numerical 
Rating Scale (NRS), and the Verbal Rating Scale (VRS)21. Their use introduces the 
risk of result bias due to pain distress and differences in the individual's 
conceptualization of pain22. Their main target is to monitor pain intensity changes, but 
they do not evaluate changes in other pain factors such as pain quality, medication, 
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pain characteristics, psychological aspects of pain, and pain coping23,24. Researchers 
have developed several pain questionnaires throughout the years to fill this gap, 
aiming to obtain a more comprehensive description of pain, including pain quality and 
concurrent symptoms25–28.  
Nonetheless, many pain questionnaires are only validated in specific patient groups, 
if validated at all. As pain can have different etiologies and characteristics, there is no 
such thing as one model to fit them all. Visceral pain is, e.g., differently characterized 
than somatic pain as it is not necessarily linked to actual or potential damage. It is 
typically a diffuse pain difficult to locate, is often associated with autonomic 
symptoms such as sweating, GI disturbances, nausea, and pallor, and it can be 
projected to remote locations29. Different chronic pain conditions can also present 
specific characteristics that differ from other types of pain and can complicate 
comparison. Therefore, questionnaires need to be either explicitly developed for or 
validated in the patient group and type of pain in question. In chronic pain, visceral 
characteristics can, however, become less evident, and central pain characteristics 
dominant. In these situations, guidelines such as the IMMPACT recommendations are 
sufficient to evaluate all etiologies of pain30. Study III and IV revolves around the 
development and validation of a pain questionnaire for pancreatic pain. 
In addition to questionnaires and pain scales, neurophysiological examination with 
quantitative sensory testing (QST) is becoming an improved way of quantitatively 
assessing pain sensation. QST serves as an addition to pain questionnaires to evaluate 
the function of the sensory system31. The QST results could potentially guide the 
physicians to which pain mechanisms are likely affected. This knowledge enables the 
possibility of targeting these mechanisms in the choice of treatment32. Previous studies 
have shown that QST results have predicted treatment response in several 
pharmacological agents33–37 or surgical interventions38,39. QST results have also been 
shown to associate with biopsychosocial mechanisms and can, therefore, be combined 
with questionnaires to provide a detailed description of different aspects of pain 31. 
Study II is an example of a study aiming to characterize pancreatic pain for QST 
examinations. 
If seeking to optimize non-pharmacological pain treatment, risk factor elimination is 
essential. In this context, knowledge of which modifiable risk factors are associated 
with maintaining chronic pain is important. Only a few studies of this kind exists, as 
most studies focus on risk factors for developing postsurgical pain, and often the 
results are non-modifiable40–42. Study I focuses on determining concurrent risk factors 
of pancreatic pain to enable risk-modifying treatment. 
In this thesis, chronic pain in patients with CP has been the focus, as this is a classic 
example of organic, visceral pain, which presents a major challenge both in pain 
evaluation and treatment.
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CHAPTER 2. BACKGROUND 
2.1. CHRONIC PANCREATITIS 
CP is a progressive fibro-inflammatory disease of the pancreatic gland43. It causes 
irreversible damage, including ductal dilation, pancreatic stones, calcification, and 
destruction of the glandular tissue. With time this can lead to exocrine and endocrine 
insufficiency. The most common reason for developing CP is long-term excessive 
alcohol intake, which accounts for around 50% of CP44. Other significant risk factors 
include smoking, nutritional factors, hereditary factors, efferent duct factors, 
immunological factors, and miscellaneous factors45. 
 
 
Figure 1: Chronic pancreatitis with fibrosis of the pancreatic tissue, calcifications, 
dilation of the pancreatic duct, pathological side branches, and pancreatic stones 
 
The most common symptom in CP is chronic abdominal pain, affecting up to 60-70% 
of patients46. The pain is typically described as a continuous severe epigastric pain, 
radiating to the back47. Pain exacerbations or intervals with reduced pain can occur in 
a constant pain pattern. The pain pattern can also be characterized as intermittent pain 
with pain-free intervals in-between48. Pain patterns can be shifting over time, as 
patients with intermittent pain later in the course of the disease can experience 
constant pain and vice versa48,49 The presence of constant pain is related to decreased 
quality of life48,50.  
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The pathophysiology of pancreatic pain is multifactorial. In some patients, there are 
obvious causes of pain. These can either be intrapancreatic (e.g., pseudocysts, 
stenosis, or obstruction of the pancreatic duct) or extrapancreatic (peptic ulcers, 
duodenal stenosis, or stenosis of the bile duct due to pancreatic fibrosis and 
inflammation affecting the surrounding structures)51. Other times, there is no evident 
anatomical cause. In these patients, pain is probably caused by the interplay between 
several factors. Although disputed, some studies of CP patients with chronic pain have 
shown pancreatic tissue hypertension, which can cause a “compartment-like 
syndrome” in the pancreas, decreasing blood flow and inducing local ischemia47. 
Hyperstimulation of the pancreatic tissue with elevated CCK level might also be a 
cause for pain, as this can increase pressure in the pancreatic duct and independently 
activate nociceptive pathways in the CNS47. Several studies have also shown evidence 
of nerve alterations with increased nerve fiber diameter and neurogenic inflammation 
leading to peripheral sensitization and neuropathy52. Together with central 
sensitization, this probably plays a central role in the development and chronification 
of pancreatic pain. Central sensitization is an important part of pancreatic pain, as it 
has been shown that many CP patients with chronic pain show signs of generalized, 
widespread sensitization: These signs include increased areas of referred pain, 
decreased pain threshold to noxious stimulations, reorganizations of brain areas 
involved in pain processing, as well as the affection of central pain modulation 
mechanisms47,53–57. 
However, not all patients with CP develop chronic pain. Risk factors for developing 
CP are well-established, but there is a lack of studies examining risk factors for 
pancreatic pain58,59. The studies that exist show that pain is equally occurring in 
alcoholic and non-alcoholic CP, but, e.g., whether concurrent alcohol and tobacco use 
is associated with pain development after CP diagnosis has not been examined60. 
Recurrent acute pancreatitis might accelerate the nervous system's sensitization, and 
is this could be a risk factor for developing pancreatic pain61. 
This lack of knowledge limits the possibility of intervention. As a result, all patients 
with CP are now advised to abstain entirely from alcohol and tobacco, as these are 
well-established risk factors for CP, but evidence on whether these substances affect 
the course of pancreatic pain is less clear. Therefore, there is a need for a study such 
as study I to enhance focus on risk factors for pancreatic pain. 
Pain has an enormous impact on the quality of life, which is significantly more 
impaired in CP than in other chronic diseases. Pain, as well as other quality-of-life 
altering complications, should therefore be an area of special attention when treating 
CP patients62. 
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2.2. NORMAL PAIN PHYSIOLOGY 
When evaluating QST measures as we did in study II, an understanding of normal 
pain physiology is essential. Pain is a protective mechanism that functions as a 
response to a damaging stimulus. The most common damaging stimulus evolves from 
the skin. The injury activates receptors at the peripheral nerves, and the signal is 
conducted through A- and C-fibres to the spinal cord, which transmits the information 
to the central nervous system (CNS)63. In the CNS, the information is processed to 
produce an appropriate response, such as retracting from the damaging stimulus. The 
receptors in the peripheral nerves can typically be activated by extreme temperatures 
(both hot and cold), mechanical stimulation, or toxins64. As a response to the 
activation of the receptor, a local action potential is generated. This action potential 
can be either up- or down-regulated due to other ligands and receptors in the peripheral 
nerve, using sodium channels to amplify the signal or potassium channels to inhibit 
the signal63. The difference between A fibers and C fibers concerns the nerve's 
diameter and the presence of myelin sheats. Therefore, the conduction speed of the 
two types of nerves is significantly different. A-fibers conduct at high velocities, are 
slowly adapting and responds throughout the duration of the stimulation. They 
typically produce a sharp and intense type of pain, while the C-fibres are more slowly 
conducting and results in a prolonged burning sensation63,64. 
The signal is transmitted through the dorsal root ganglion cells/trigeminal ganglion 
cells in the spinal nerve's dorsal root. Then it is forwarded through the spinothalamic 
tract via the thalamus to the cerebral cortex and various subcortical regions, and the 
medulla and brainstem through the spinoreticular and spinomesenchephalic tracts65–
67. 
Visceral pain is differently transmitted than somatic pain, and the sensation of this 
type of pain is also quite different. Afferent spinal nerves innervate the viscera68. 
These are unmyelinated, thin nerves conducting at low velocities. Most of the visceral 
afferent nerves pass through para- and pre-vertebral ganglia to the spinal cord, where 
they terminate at several segmental levels. In the spinal cord, the fibers can converge 
with somatic fibers, which can explain referred pain to somatic structures, often 
present in visceral pain. 
Additionally, the fibers project to the spinal cord with the same nerves as the 
sympathetic fibers, leading to local and central crosstalk69. This cross-talk can induce 
autonomic reflexes, tension of the muscles, and over time trophic alterations in 
somatic tissue69. Vagal nerves also play a role in the visceral pain nociception, 
normally as a part of central inhibitory pain modulation69. 
 




Figure 2: The nociceptive system 
 
Nociception in the CNS is complex, with no single pathway being solely responsible 
for pain perception. Several aspects of pain are processed in the CNS, including 
somatotropic, emotional, intrinsic, and mechanical63. 
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Figure 3: The descending pain modulatory systems. +/- indicates influences that are 
either pro- or anti-nociceptive, respectively 
 
The brain can actively regulate sensory transmissions through the descending pain 
modulatory systems, and this enables us to regulate the information either by 
facilitation or inhibition depending on, e.g., stimulus intensity or context66. There is 
evidence of several brain regions' involvement in the descending modulation. These 
regions include the frontal lobe, anterior cingulate cortex, insula, amygdala, 
hypothalamus, periaqueductal gray, nucleus cuneiformis, and the rostral ventromedial 
medulla66. Through reciprocal connections, they mediate nociceptive inputs from 
various sites66,70.  
It has been suggested that the pain modulatory systems function as a filter. This filter 
allows the brain to focus on one noxious stimulus while other sensory stimuli affect 
different parts of the body71. The modulatory systems are relevant in a situation with 
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an immediate threat to life, where suppression of pain will increase the risk of 
surviving by enabling the body to either fight or flight65.  
The thalamus is also involved in nociception, as it is involved in converting the pain 
perception into a reasonable response guiding human behavior away from the 
damaging stimulus72. 
 
2.3. PAIN MECHANISMS 
When pain becomes a chronic state, the nervous system might become sensitized. It 
affects local nerves, leading to peripheral sensitization, progressing to ipsilateral 
sensitization, segmental sensitization, extraterritorial sensitization, and finally, 
generalized, widespread central sensitization hypersensitivity is present in several 
somatic structures unrelated to the primarily affected area73. 
 
2.3.1. PERIPHERAL SENSITIZATION 
Nociceptors are capable of adapting due to axon injury or exposure to inflammation. 
This adaption can lead to continuous signaling without noxious stimulation, causing 
chronic pain due to the nociceptor's sensitization by reducing the stimulation 
threshold, increasing responsiveness, and developing spontaneous discharges67,74. 
 
2.3.2. CENTRAL SENSITIZATION 
Central sensitization is an enhancement in the function of the neurons and neurogenic 
circuits in the nociceptive pathways75. This enhancement is caused by changes in 
membrane excitability, inhibition, or synaptic efficacy due to the highly malleable 
nature of the nociceptive systems75. Due to the changes in synaptic efficacy, effects 
similar to peripheral sensitization changes occur, including increased spontaneous 
discharge, lower activation threshold, and an increased response to suprathreshold 
stimulations75. 
The patient becomes hyperalgesic with decreased pain threshold and increased 
response to a painful stimulus in both magnitude and duration76. In some patients, this 
progresses into tactile allodynia, where a normally non-painful stimulus elicits pain77.  
Central sensitization is characterized by, e.g., hypersensitivity, increased temporal 
summation, and defective descending pain modulation. Temporal summation is 
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defined as an increase in pain perception through repetitive painful stimulations78. It 
is an electrophysiological phenomenon where postsynaptic neurons respond to 
stimulations between 0.5 and 5 Hz by increasing discharge in the first 10-30 stimuli, 
and hereafter reaching a plateau77. In generalized, widespread sensitization, the 




Figure 4: Temporal summation 
 
2.3.3. DEFECTIVE DESCENDING PAIN MODULATION 
In case of dual concurrent pain stimulation, under normal circumstances and in the 
absence of chronic pain conditions, the descending pain modulation will provide 
inhibition of nociceptive input from one of the pain stimuli, which is commonly 
described as 'pain-inhibits-pain,' 'counter-irritation,' 'diffuse noxious inhibitory,' or 
CPM79,80. The latter term will be used in the remainder of the thesis. 
The amount of pain modulation in healthy adults differ significantly. The differences 
may be due to gender- and age-variation, and we performed a QST study examining 
these variations and proved that gender variation was significant, but age-variation 
was of limited effect size56. Other unknown factors can also affect the results81,82. 
While CPM capacity is a prognostic factor for, e.g., developing post-operative 
pain39,80, the sex-variation is relevant to bear in mind if using it clinically. 
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While the modulatory systems can be essential for pain analgesia, descending pain 
modulation can also play a crucial role in developing and maintaining chronic pain. 
This opposing effect happens as an imbalance in the systems can facilitate 
nociception70,83. Several animal studies on neuropathic pain support this theory. They 
find evidence that descending facilitation of pain is increased in models of chronic 
neuropathic pain84,85. Evidence of dysfunction of descending pain modulation has also 
been found in several chronic pain types, including CP35,86–88. The effectiveness of 
pain inhibition has been shown to predict, e.g., the analgesic treatment response of 
duloxetine35. In other studies, no correlation has been found with the treatment 
response of pregabalin33 or placebo89. 
 
2.3.4. COGNITIVE MODULATION 
The pain modulatory systems also provide a pathway where negative emotions and 
stress can aggravate and extend the duration of pain65. Pain perception is vastly 
affected by psychological, cognitive, affective, and behavioral processes. Attention to 
pain has been extensively examined, as pain is perceived less intense during 
distractions, both auditory, visual, tactile, or cognitive90,91. As an example, a painful 
stimulus was conducted on healthy volunteers two times. The patients were asked to 
solve mentally challenging tasks during one of the stimulations, and the two results 
were then compared. The results were significantly lower pain ratings while being 
mentally distracted compared to the undistracted pain stimulation91.  
Emotional factors can also alter pain perception. A study found that pleasing 
stimulations positively affected emotional state in an experimental context, e.g., music 
and pleasant pictures reduced pain perception90. Negative emotions are associated 
with increased activity in the amygdala, the anterior insula, and the anterior cingulate 
cortex, which are essential parts of the pain modulatory system. It is, therefore, 
hypothesized that these emotions could facilitate nociception65. The precise cause of 
this effect is, however, not yet elucidated. The fact that chronic pain affects the mental 
state of mind also complicates the clarification.  
Previous studies have found that fear of pain and other negative emotions can increase 
pain perception, but it is unclear whether the changed pain perception results from the 
increased fear of pain alone or perhaps an interplay with pain catastrophizing92. 
Studies on psychological aspects of pain should also be evaluated with caution, as it 
is difficult to distinguish the effects of changed emotional status from the impact 
caused by a change in attention towards pain.  
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2.4. PAIN ASSESSMENT 
Pain assessment is notoriously tricky due to the subjective nature of pain and the 
complexity of pain perception. To truly measure the span of the experience of pain, 
several modalities will have to be combined. Psychometric tests such as 
questionnaires can evaluate both intensity, quality, and effect on daily-life, while 
quantitative sensory testing can provide a sensory profile of the patient93,94. Even in 
QST measures, the response is evaluated subjectively as pain intensity. Despite this, 
pain assessment is essential when evaluating treatment response, and a follow-up 
regimen must naturally include a minimum of one measure of pain assessment. Study 
III and IV were performed to develop a valid, reliable, and feasible questionnaire 
developed explicitly for pancreatic pain. 
 
2.4.1. PAIN SCALES 
Unidimensional pain scales are widely used in both medical departments and in 
research to assess pain intensity. Nevertheless, as the interpretation of pain intensity 
reflects on the individual's concept of pain, these ratings are highly subjective and can 
only be used to assess change in pain intensity, rather than being comparative95. 
 
2.4.2. PAIN QUESTIONNAIRES 
The concept of pain differs from patient to patient, as many things are incorporated in 
the pain sensation. This is evident as many patients lack to define sensations such as 
tingling, numbness, and paresthesias as pain23. Pain sensation is equally affected by 
other pain-related symptoms, such as nausea, sleep disturbances, and fatigue, which 
may exaggerate the pain sensation94. Mood and degree of disability can also bias the 
pain assessment23. These facts sum up that psychometric instruments must be 
thorough and elaborative, but even so, interpreted with caution. To choose the most 
suitable tool for the specific situation, physicians must consider whether the 
questionnaire collects the necessary data without compromising the feasibility and 
simplicity needed to get reliable answers. 
When using questionnaires to evaluate pain, it is essential that the questionnaire is 
reliable and validated. Like mechanical and electrical instruments, questionnaires are 
precision measurement instruments that need to be tested thoroughly to guarantee 
validity. Therefore, numerous trials precede validation, and even small changes can 
destroy the result. 
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Validation of a questionnaire can include four aspects. 1) Face validity, where a group 
of non-experts in methodologies assesses the questionnaire as to whether the test 
seems valid. 2) Content validity, a systematic evaluation of the questionnaire by a 
group of experts, assessing whether all essential parts of the subject are covered. 3) 
Construct validity, which can consist of two parts. Convergent validity assesses 
whether related questions correlate, and discriminant validity where un-related 
questions should show no or only minor associations. 4) Criterion validity, where the 
relationship to concurrent or future clinical outcomes are examined. These outcomes 
can either be clinical factors such as quality of life, opioid-use, hospitalizations, 
surgeries, or scores from related questionnaires96. 
Unfortunately, there is no validated pain questionnaire developed specifically for 
patients with CP, which stresses the need to develop such a questionnaire, as done in 
study III. The abdominal pain experienced in CP fits visceral pain characteristics as 
diffuse and poorly localized and involving autonomic and motor reactions such as 
nausea, sweating, and palpitations97. These features complicate comparison with, e.g., 
musculoskeletal pain, and a questionnaire developed for, at the least, visceral pain is 
essential to enlighten the pain characteristics fully. The Izbicki pain score98, the Brief 
Pain Inventory (BPI)99, and the McGill Pain Questionnaire25 have frequently been 
used to evaluate pancreatic pain, although only the BPI is strictly validated in CP 
patients100. 
A new pain assessment questionnaire has recently been developed for chronic 
pancreatitis patients, the "COMprehensive Pain Assessment Tool (COMPAT) for 
chronic pancreatitis"101. This is a thorough and elaborate pain questionnaire covering 
all essential aspects of pain in CP, including pain pattern, pain intensity, pain 
provoking factors, pain-relieving factors, social and emotional factors, risk factors for 
pain, and pain treatment, both pharmaceutical and surgical. Its elaborate form makes 
it time-consuming to complete, making it less suitable for clinical practice and 
primary evaluation. 
 
2.4.3. QUANTITATIVE SENSORY TESTING 
QST is a method for quantifying a loss or gain of sensory function in the neural axis 
to increase our knowledge of the origin of dysfunction leading to chronic pain 31. It 
can include various tests designed to examine the sensory function of pain perception 
from receptor to brain, including different afferents and central pathways31. Possible 
stimulation modalities include thermal, mechanical, chemical, electrical, and ischemic 
stimulations. Stimulation sites are typically cutaneous, but visceral stimulations have 
also been used31,102. As QST examination responses only are semi-objective, results 
are only valid if the patient is well-instructed and cooperative103.  
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The use of QST in pain evaluation is increasing, and as the examinations are 
advancing, it is now possible to point out which pain mechanisms possibly are 
dysfunctional from the QST evaluations102. In recent years, this has led to QST 
gaining ground in predicting treatment response, and research in this area is increasing 
year by year33,88,104,105. 
Comprehensive QST batteries, including numerous examination modalities, have 
previously been used when examining pain sensitivity in chronic pain patients106. 
While these can function in the context of research, they are not suited for clinical 
practice, where time is limited, and examinations must be quick and efficient.  
We have previously used visceral pain models to explore the pain system, but these 
are invasive and cumbersome to use57,107–110. As somatic and visceral fibers converge 
in the same segments of the spinal cord and share central mechanisms, quantitative 
sensory testing of the skin can be used to determine the functioning of the visceral 
nociceptive system indirectly. A combination of pinprick, mechanical and thermal 
stimuli can unravel whether the pain is localized to the pancreatic dermatome where 
it is considered reversible or spread to several spinal segments and the brain, causing 
widespread sensitization. It can also be determined whether there is abnormal 
activation of specific pain mechanisms reflecting chronification. These are a) central 
integration to repeated stimuli and b) efficacy of descending pain inhibition from the 
brainstem to the spinal cord, gating the afferent barrage from pancreatic nerves. 
Together with an assessment of the pain experience and psychological comorbidity, 
such QST has the potential to be a powerful instrument to determine the pain 
phenotype and guide treatment, but more evidence is needed before it can be used in 
clinical practice. In study II we tested a feasible, bedside QST paradigm designed to 
evaluate pancreatic pain efficiently. 
 
2.4.3.1 Peripheral and generalized widespread sensitization 
Optimally, the sensitization of the central nervous system is assessed using 
electrophysiological recordings from central neurons. However, this is not a viable 
measure in humans, and sensory evaluation of the nervous system's nociceptive 
excitability is a decent surrogate marker111. The pain detection threshold and pain 
tolerance threshold can provide information in this assessment by comparing it with 
normative data56. Typically, thresholds are examined in several locations throughout 
the body to examine differences and distinguish between peripheral sensitization and 
central sensitization. If lower thresholds are present locally, it can be caused by 
peripheral sensitization due to tissue injury with a resulting outlet of inflammatory 
mediators that activates signaling cascades in the sensory neuron112. Thresholds can 
also be lowered in several locations, independent of proximity to present 
injury/disease, indicating central sensitization111. Evaluation of several sites, 
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including sites unrelated to the anatomically affected area, is therefore essential. 
Figure 5 shows different evaluation sites used in study II, which gives the possibility 
to evaluate peripheral and generalized widespread sensitization in CP patients. 
 
Figure 5: Evaluation sites that allow the evaluation of the presence of peripheral 
and widespread sensitization 
 
2.4.3.2 Wind-up ratio 
The wind-up ratio is the proportion of increased pain intensity caused by a series of 
repetitive, rhythmical, painful stimulations compared to a single stimulus. An 
increased wind-up ratio is caused by temporal summation. The wind-up ratio can be 
assessed by using, e.g., mechanical, thermal, or electric stimuli111,113. The patient is 
asked to rate one stimulus in pain intensity, and afterward, a series of at least five 
stimuli are applied. The patient is asked to rate the series intensity as a whole, and a 
ratio between the two intensities is calculated114. 
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2.4.3.3 CPM 
CPM estimates the change in pain perception after a conditioning stimulus. A wide 
variety of conditioning stimuli have been used, but the two most commonly used are 
cold water or ischemia115. The pain detection threshold or pain tolerance threshold to 
a given stimulus is assessed before and after the conditioning stimulus, and the values 
are compared. The threshold is typically significantly higher after the conditioning 
stimulus than before. Patients with deficient CPM capacity will often not be able to 
raise the threshold, and in some, it will be lowered despite the conditioning stimulus. 
CPM capacity is deficient in various chronic pain conditions, including CP54,116–118, 
and recent studies suggest that different analgetic treatments can affect the pain 
modulation35,86,119,120. In a study by Bouwense et al., pregabalin was shown to increase 
conditioned pain modulation in a group of responders where nearly half had 
widespread hyperalgesia119. 
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CHAPTER 3. HYPOTHESIS AND AIMS 
The objective of this Ph.D. was to optimize methods of evaluating and quantifying 
pain in patients with CP. Thus, it was hypothesized that chronic pancreatic pain could 
be thoroughly assessed by evaluating the following disease-specific factors: 1) pain 
risk elements, 2) quantitative sensory testing (QST), and 3) pain questionnaires. 
The thesis is based on a peer-reviewed narrative literature review, two published 
original papers, and a paper submitted for publication. The three original papers were 
based on four studies: 
Study I is a cross-sectional study that assesses chronic pain prevalence in patients with 
CP and associated pain risk factors.  
Study II is a cross-sectional study investigating QST results in patients with painful 
CP and comparing these with clinical features.  
Study III is a cross-sectional study focused on developing a short form of the pre-
existing COMPAT-questionnaire, which is made explicitly for patients with painful 
CP.  
Study IV is a prospective study designed to evaluate the reliability and validity of the 
COMPAT-SF questionnaire. 
 
Figure 6: Overview of the Ph.D. studies, papers, and aims 




1. To review the literature to develop a mechanism-based treatment algorithm 
2. To determine the prevalence of pain in a multicenter cohort of Scandinavian-
Baltic patients with CP 
3. To determine associations between disease characteristics and presence and 
pattern (intermittent vs. constant) of pancreatic pain 
4. To show that a simple, bedside QST regime can be used to characterize 
differences in pain sensitivity between CP patients and healthy volunteers 
and investigate associations between pain sensitivity and clinical 
characteristics 
5. To use the newly developed chronic pancreatitis specific questionnaire 
(COMPAT) to form a feasible screening instrument (SF-COMPAT) 
6. To validate the developed COMPAT-SF on content and construct, as well as 
criterion validity 
7. To test the SF-COMPAT for reliability in two patient cohorts with chronic 
constant and unstable pain. 
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CHAPTER 4. METHODS 
Data for this thesis was collected from four studies. All studies comply with the 
Declaration of Helsinki and International Conference on Harmonization Good 
Clinical Practice Guidelines. 
 
4.1. STUDY I 
Study I was a cross-sectional study based on data from the Scandinavian Baltic 
Pancreatic Club (SBPC) database46. The SBPC database is an open, continuously 
recruiting prospective multicenter registration of patients with CP. The database was 
started in February 2016 and is continuously recruiting46. The data were obtained by 
the 1st of January 2019 and included 1384 CP patients from 11 centers in seven 
countries in the Scandinavian-Baltic-Russian region121. 
Patients characterized as having definitive or probable CP, according to the M-
ANNHEIM classification system45, were included in the study. The only exclusion 
criterion was a history of pancreatic cancer. 
Information in the database was obtained from patient interviews and a review of the 
patient's medical records, including biochemistry. The treating physician identified 
etiological risk factors based on the M-ANNHEIM classification system, where more 
than one etiology can be assigned to the individual patient. No threshold for risk 
factors was applied45. 
Data derived from the database included 
• Gender and age 
• Duration of CP 
• Etiological risk factors for CP 
• Presence of diabetes and exocrine pancreatic insufficiency (EPI) 
• Pain pattern 
• Imaging abnormalities, including pancreatic calcifications, pseudocysts, and 
common bile duct or duodenal stenosis 
• Current alcohol consumption 
• Current smoking pattern 
Pain pattern was characterized as either no pain, intermittent pain, constant pain, or 
constant pain with acute exacerbations100. The primary analysis compared patients 
with no pain against patients with pain to uncover potential associations between risk 
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factors and the presence of pain. The secondary analysis compared associated risk 
factors for intermittent or constant pain, where constant pain and constant pain with 
acute exacerbations were pooled into the latter. The focus was on the current pain 
pattern, regardless of previous classifications, to uncover the association between 
current risk factors and the presence of pain/present pain pattern. The importance of 
defining pain pattern is evident from earlier studies, as it has a significant effect on 
rates of disability, hospitalization, use of analgesic medications, and quality of life48.  
Patients current alcohol consumption was measured as alcohol units ingested per 
week, and patients were divided into five groups122: 
1. Abstainers (no alcohol use) 
2. Light drinkers (≤ three units per week) 
3. Moderate drinkers (four to seven units per week for women and four to 14 
units per week for men) 
4. Heavy drinkers (eight to 34 units per week for women and 15 to 34 units per 
week for men) 
5. Very heavy drinkers (≥ 35 units per week) 
 
Smoking habits were registered as the number of cigarettes smoked per day, and the 
patients were divided into four groups123: 
1. Non-smokers (past or never) 
2. Light smokers (< 10 cigarettes per day) 
3. Moderate smokers (10-20 cigarettes per day) 
4. Heavy smokers (> 20 cigarettes per day) 
 
The demographical information and clinical features were compared between patients 
with and without pain. Multivariable model development and analysis was performed 
to detect independent associations between clinical factors and the presence of pain 
and pain patterns124. In the primary analysis, logistic regression with backward 
selection was performed, including removing variables one after another depending 
on the significance level. As diabetes was considered clinically relevant, it was forced 
back into the model124. As marked pancreatic duct pathology and pancreatic 
calcifications expressed a linear relationship, pancreatic calcifications were omitted 
from the model. A nested log-likelihood test was performed to examine the interaction 
between smoking and alcohol intake, comparing models including the single variables 




4.2. STUDY II 
Study II was a cross-sectional study aiming to characterize CP patients' sensory 
profiles based on QST results, including data from a previous study conducted in 
Denmark and the Netherlands126. 
The study included 91 CP patients and 28 healthy controls. Patients' inclusion criteria 
included a diagnosis of CP by a Lüneburg score ≥ 4 and abdominal pancreatic pain, 
either intermittent or constant127,128. The control group's inclusion criteria included no 
major chronic diseases, absence of chronic pain, and no regular use of any analgesics. 
A detailed medical history was recorded for all patients, including pain localization 
and characterization, comorbidities, alcohol and tobacco use, and medications. All 
patients completed a pain questionnaire and a quality of life questionnaire (BPI129 and 
The European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C30)130) and kept a daily pain diary one week before 
the examination. 
In this study, a simple, bedside-suitable QST sequence developed in collaboration 
between Denmark and the Netherlands (the Nijmegen-Aalborg Sensory QST (NASQ) 
paradigm131) was applied. Only the most often affected pain mechanisms were 
examined. The specialized equipment needed has also been kept to a bare minimum, 
and the sequence consisted of only three examination modalities. 
The QST sequence was performed on all patients and healthy volunteers by one of 
three trained QST investigators. 
 
4.2.1. STATIC QST ASSESSMENT 
The static QST assessment in study II consisted of two stimulation modalities, 
pressure stimulation and electrical stimulation. Five different stimulation sites on the 
patient's right side were examined, including: 
1. Below the clavicular midline (C5 dermatome) 
2. The abdominal, pancreatic area above the umbilicus (abdominal Th10 
dermatome) 
3. Dorsal pancreatic area, just lateral of the spine (dorsal Th10 dermatome) 
4. The anterior, superior, iliac spine (L1 dermatome) 
5. Quadriceps muscle 5 cm proximal to the patella (L4 dermatome) 
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Pressure stimulation thresholds were obtained using a pressure algometer with a 1.0 
cm2 probe (Somedic AB, Stockholm, Sweden). Pressure pain detection threshold 




Figure 7: Pressure algometer 
 
The electric constant skin stimulation thresholds in study II (Digistim; Biometer A/S, 
Copenhagen, Denmark) were measured using tetanic stimulation at 100 Hz, using two 
electrodes placed 3 cm apart. The equivalents of the two pressure thresholds were 
determined (electrical pain detection threshold (ePDT) and electrical pain tolerance 
threshold (ePTT))55,126. 
 




4.2.2. DYNAMIC QST ASSESSMENT 
In study II, CPM capacity was quantified by the cold pressor test, where the 
conditioning stimulus was cold water (2.0°C ± 0.3°C, continuously stirred), and the 
test stimulation was pressure stimulation with a pressure algometer on the L4 
dermatome, 5 cm above the patella. During the conditioning stimulus, the patient's 
dominant hand was immersed in the cold water for two minutes133.  
 
 
Figure 9: Cold pressor test 
 
If the pain became unbearable before the two minutes were over and distraction was 
insufficient to enable the continuation of the stimulation, the participants could 
remove the hand from the water ahead of time. Pressure stimulation estimating pPTT 
was applied before and immediately after the conditioning stimulus on the quadriceps 
muscle 5 cm proximal to the patella on the non-dominant side. 
The CPM capacity was established as the absolute and relative changes in pPTT 
before and after the conditioning stimulus. 
Demographics, clinical information, and CPM parameters of CP patients and controls 
were compared using the student’s t-test, fishers exact test, and 1-way analysis of 
variance with Bonferroni corrections. Electrical and pressure thresholds were log-
transformed before using a mixed-effects model to compare the groups. 
Subgroup analysis of clinical parameters and associated QST parameters were 
performed using univariate and multivariate regression analysis. 
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4.3. STUDY III AND IV 
Study III was a cross-sectional study. It was designed to develop a short form of the 
COMPAT questionnaire, a pain questionnaire created explicitly for patients with CP 
and acute recurrent pancreatitis. It included patients from a center in New Zealand and 
a center in Denmark. Inclusion criteria included painful CP diagnosed by a Mayo 
score ≥ 4134. Exclusion criteria included under 18 years of age, severe comorbidities, 
acute pancreatitis, autoimmune pancreatitis, and CP secondary to malignancy. 
Patients filled out the full version of the COMPAT questionnaire101, including 23 main 
questions and 180 secondary questions. The questionnaire was developed in English 
but translated to Danish for the Danish patients. The translation was back-translated 
to English by a native Danish speaker with in-depth knowledge of the English 
language, demonstrated by an International English Language Testing (IELTS) score 
of 8.5, corresponding to a native English speaker. Any inconsistencies were discussed 
with the original authors to ensure no decline in the nuance of the language. Part of 
the original McGill questionnaire was incorporated in the COMPAT questionnaire, 
and the translation of this part was based on a previously validated translation135. 
Study IV was designed to test the reliability and validity of the COMPAT-SF 
questionnaire. The study was conducted at three centers in Aalborg, Denmark, 
Pittsburgh, USA, and Baltimore, USA. Inclusion and exclusion criteria were the same 
as in study III. Inclusion of patients from Aalborg and Pittsburgh was focused on 
patients with a stable pain status. Stable pain status was defined as no surgical or 
endoscopic interventions, and no major pain medication changes six months before 
inclusion. All eligible patients, regardless of fluctuating pain, could be included from 
the center in Baltimore. This difference was designed to exemplify whether 
fluctuating pain levels could influence the reliability and enhance knowledge of CP 
reliability studies' difficulties. The sample size was determined to detect a possibly 
significant correlation between the two answers of the COMPAT-SF questionnaires. 
Alpha was set at 0.05, beta at 0.2, intraclass correlation coefficient (ICC) below 0.60 
was considered not relevant, and from a hypothesized ICC of 0.80, the sample size 
was calculated to be a minimum of 40 participants. 
Seventy-six patients were included for the reliability study, 51 were from the stable 
pain status group, and the subject to item ratio was thereby 8.5. To validate the 
COMPAT-SF questionnaire, all patients completed the COMPAT-SF questionnaire, 
the Izbicki pain scale98, and the BPI pain questionnaire129 at baseline. After 2-6 weeks, 
patients completed a second COMPAT-SF. Forty-one patients from the stable pain 
status group and 25 patients from the unstable pain status group fulfilled the trial and 
completed both COMPAT-SF questionnaires. Reliability was examined by 
comparing the first and second completion of the COMPAT-SF questionnaire. 
For an overview of the course of the two studies, please see figure 10. 
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Figure 10: Development, validation, and reliability testing of the short form 
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Questions to include in the COMPAT-SF were chosen based on the content of the 91 
patients' questionnaire answers. 
To allow for statistical calculations, answers were interpolated if a limited number of 
secondary questions were left blank (<20%). Interpolation was performed by carefully 
finding patients who had answered correspondingly in the other secondary questions 
and choosing a relevant response from their questionnaire fulfillments. If a main 
question was left entirely unfilled, no interpolation was performed to limit the 
answers' uncertainty. 
Four questions were designed to be answered by subgroups of patients according to 
their pain pattern (question 10 – 13). The pain intensity secondary questions from 
these questions were merged into one pain intensity question to enhance the item 
response rate and simplify the questionnaire. 
The distribution of answers in the remaining questions was inspected, and items with 
pronounced flooring or ceiling effect above 20% were excluded. This was done to 
minimize the risk of type I errors136,137. 
Then all unclear or irrelevant questions were omitted. A question was deemed 
irrelevant or unclear based on the completion rate, where below 80% was considered 
the cut-off value138.  
At last, all supportive and not directly pain-related questions were excluded. These 
were dropped to limit the number of questions in the short form. Although it is advised 
that factors such as sleep, sexual function, quality of life, and psychological aspects 
of pain are evaluated in chronic pain patients, these are more universal aspects of pain, 
and questionnaires developed for chronic pain conditions in general can easily be 
used.  
If multiple questions from the same pain dimension remained, their scores were 
merged into one mean pain dimension score. All pain dimension scores were 
normalized on a 0-100 scale and weighted according to clinical relevance. 
 
4.3.2. VALIDATION 




Content validity was assessed by an expert panel consisting of the original COMPAT 
questionnaire's developmental team and specialists in pancreatic pain by ensuring that 
all essential pain dimensions from the original COMPAT questionnaire were 
included139. 
Construct validity was ensured by performing confirmatory factor analysis (CFA) on 
the included pain dimensions140. 
Criterion validity was assessed in two ways: 1) by comparing the COMPAT-SF scores 
with hospitalization days during the past year and the Pancreatitis Quality of Life 
Instrument  (PANQOLI) score141 from the full COMPAT questionnaire, using 
negative binomial regression and linear regression. 2) By correlating the COMPAT-
SF total score against the BPI scores and the Izbicki pain questionnaire using 
Pearson’s correlation coefficient96. 
 
4.3.3. RELIABILITY 
Reliability was assessed by comparing the answers from the first and the second 
COMPAT-SF from the reliability study using the ICC and Bland-Altman plots. 
Internal consistency was examined by calculating Cronbach’s alpha, as the 
questionnaire is developed to be unidimensional96. 
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CHAPTER 5. KEY RESULTS 
5.1. AIM   I 




• No single analgesic is the best match for every patient 
• QST and psychological evaluation could provide a platform for individualized 
and multimodal pain management 
• A proposed treatment algorithm is provided, although the overall concept is not 






Figure 11: The flowchart exemplifies a mechanism-based treatment algorithm that 
can be used to guide pain management in CP patients. Abbreviations: GABA = 
gabapentinoids, QST = Quantitative Sensory Testing, SNRI = Serotonin and 
Norepinephrine Reuptake Inhibitor, TCA = Tricyclic Antidepressants, CBT = 
Cognitive Behavioral Therapy. 
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5.2. AIM II 
Aim: To determine the prevalence of pain in a multicenter cohort of Scandinavian-
Baltic patients with CP (paper II). 
Key results: 
• Nearly 60% of patients reported pain, of whom 71% reported intermittent pain, 
19% constant pain with acute exacerbations, and 10% constant pain. 
 
 
5.3. AIM III 
Aim: To determine associations between disease characteristics and presence and 
pattern (intermittent vs. constant) of pancreatic pain (paper II). 
Key results: 
• Pain associated disease characteristics confirmed by multivariate analysis 
included: 
• Very heavy alcohol abuse (> 5 units of alcohol per day) 
• An increasing number of cigarettes smoked per day increased the risk of 
painful CP 
• Exocrine insufficiency 
• Moderate pancreatic duct changes 
• Pseudocysts 
• Duodenal stenosis 
• Associations between pain pattern and disease characteristics confirmed by 
multivariate analysis included 
• Smoking habits, as moderate and heavy smokers were more likely to report 
constant pain 
• Active alcohol consumers were more likely to report intermittent pain 
• Moderate to marked ductal changes in the pancreas trended towards 
associating with constant pain 







5.4. AIM IV 
Aim: To show that a simple, bedside QST regime can be used to characterize 
differences in pain sensitivity between CP patients and healthy volunteers and 




• CP patients were hypersensitive to pressure stimulation at the dorsal pancreatic 
dermatome, the abdominal pancreatic dermatome, and the L4-control dermatome 
compared to healthy controls 
• Likewise, CP patients were hypersensitive to electrical stimulation at the dorsal 
pancreatic dermatome and the L4 dermatome 
• The cold pressor test showed that the tolerated duration was lower in CP patients 
than in healthy controls. 
• CPM: The patients had lower pPTT before and after the cold pressor test, and the 
change between the two was significant. There was no correlation between the 
duration of the cold pressor test and the CPM response. 
• Clinical pain intensity was significantly associated with low CPM response 
• Pain interference score on the BPI questionnaire was associated with average 




5.5. AIM V 
Aim: To use the newly developed chronic pancreatitis specific questionnaire 
(COMPAT) to form a feasible screening instrument (SF-COMPAT) (paper IV) 
Key results: 
• The developed COMPAT-SF questionnaire is comprised of five pain dimensions 
containing six questions. The total COMPAT score includes all of the dimensions 




PAIN IN PATIENTS WITH CHRONIC PANCREATITIS 
50
 
5.6. AIM VI 
Aim: To validate the developed COMPAT-SF on content and construct, as well as 




• Content validity: All experts in the focus group agreed that the questionnaire 
contained the most relevant aspects of the full COMPAT questionnaire and would 
be suited to use as a brief questionnaire for research, in clinical, or as a screening 
tool for further investigation using the full COMPAT questionnaire. 
• Construct validity: CFA found highly significant factor loadings for all five 
factors (pain dimensions), ranging from 0.44-0.78 (p<0.001). The four strongest 
factors all had R2 values above 0.3 and an overall factor R2 value of 0.81. 
• Criterion validity: The COMPAT-SF total score correlated significantly with the 
Izbicki Pain Scale and the BPI (p<0.0001). The highest correlation coefficient 
was with the Izbicki Pain Scale (0.78 vs. 0.61, respectively). 
• Criterion validity: The COMPAT-SF total score and three of the subscores (pain 
pattern, pain severity, and pain provocation) were significantly correlated to 12 
months hospitalization rates (p<0.05). The COMPAT-SF total score and all 
subscores were significantly correlated with quality of life (p<0.05). 
 
5.7. AIM VII 
Aim: To test the SF-COMPAT for reliability in two patient cohorts with chronic 




• Reliability in the COMPAT-SF was good, with an ICC of 0.89 in the stable pain 
group. However, the limits of agreement were above average but acceptable. The 
ICC in the unstable pain group was only moderate (0.61) with very high 
insecurities of approximately ±30%. 
• The Cronbach‘s alpha of the COMPAT-SF questionnaire was good at 0.77 with 
a confidence interval of 0.7 – 0.82, indicating good internal consistency.
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CHAPTER 6. DISCUSSION 
The Ph.D. thesis had seven objectives: 
1. To review the literature to develop a mechanism-based treatment algorithm 
2. To determine the prevalence of pain in a multicenter cohort of Scandinavian-
Baltic patients with CP 
3. To determine associations between disease characteristics and presence and 
pattern (intermittent vs. constant) of pancreatic pain 
4. To show that a simple, bedside QST regime can be used to characterize 
differences in pain sensitivity between CP patients and healthy volunteers 
and investigate associations between pain sensitivity and clinical 
characteristics 
5. To use the newly developed chronic pancreatitis specific questionnaire 
(COMPAT) to form a feasible screening instrument (SF-COMPAT) 
6. To validate the developed COMPAT-SF on content and construct, as well as 
criterion validity 
7. To test the SF-COMPAT for reliability in two patient cohorts with chronic 
constant and unstable pain. 
The discussion is divided into two parts, first concerning methodological 
considerations in pain assessment of CP patients, hereafter a discussion on clinical 
implications and future perspectives of performing a comprehensive pain assessment, 
including several layers to establish as precise an estimation of pain intensity, quality, 
and life interference as possible. 
 
6.1. METHODOLOGICAL CONSIDERATIONS 
6.1.1. DIAGNOSTIC CRITERIA 
The thesis is based on four different studies performed in collaboration with several 
teams from around the world. This background has resulted in structural differences, 
for instance, concerning different ways of diagnosing CP. Study I was based on data 
from the SBPC database, a database formed from a collaboration between several sites 
in the Scandinavian and Baltic regions. For this database, the steering group had 
agreed upon using the M-ANNHEIM diagnostic criteria. Study II was a study based 
on patients from Aalborg, Denmark, and Nijmegen, The Netherlands. Data collection 
was started as a part of a different study in which the Lüneburg criteria were used as 
a diagnostic inclusion criterion. Afterward, further data collection was conducted, 
naturally maintaining the primary inclusion criteria. Studies III and IV were 
performed in collaboration with teams in New Zealand and the United States of 
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America. As the diagnostic criteria used in these two countries are the Mayo criteria, 
it was natural to adopt these criteria to the inclusion criteria. 
The usage of three different diagnostic methods could raise doubt about whether the 
patients in the four studies are comparable. The Lüneburg criteria and the Mayo 
criteria are generally quite similar, but the Lüneburg criteria also account for indirect 
pancreatic function tests and findings on ultrasonic and diagnostic procedures. The 
M-ANNHEIM diagnostic criteria are mainly focused on the presence of either 
calcifications or marked ductal alterations and persistent exocrine insufficiency as 
definite diagnostic criteria for CP142. These criteria are generally present in all the 
different diagnostic methods for definitive CP. Therefore, the diagnostic criteria used 
will probably not affect the result, as all patients included in the studies had definite 
CP. 
 
6.1.2. DATABASE STUDIES 
The design of study I was based on data from a continuously recruiting database. The 
database design provides a basis for gathering a large amount of data. The amount of 
data is essential when conducting outcomes analyses, as large datasets enable the use 
of multivariate analysis that can be used on complex datasets with several potential 
factors of significance.  
Examining large datasets typically produce estimates with smaller confidence 
intervals, making the results more reliable and form the basis for hypothesis 
development143. Database design can also present challenges, as the data input often 
is less than perfect, which leaves room for biases as to which patients have incomplete 
registration. The causes for the incomplete data entry are almost impossible to detect 
post hoc. Variation in data quality can also be a problem concerning the consistency 
of coding, which is difficult to bypass when the database collaborates between 
different centers. When examining a disease like CP, multicenter collaborations are 
essential, as the disease is not a frequently occurring disease, limiting the availability 
of patients. Therefore other centers can help in establishing a large patient cohort for 
the database. To avoid coding inconsistencies in the SBPC database, a steering group 
is in charge of establishing standard ground rules that are followed universally at all 
sites. These ground rules have been established through frequent contact and meetings 
in the steering group.  
To ensure comparability in the collected data, all included centers in the SBPC 
database are secondary or tertiary referral centers with a particular interest in CP46. 
In study I, the prevalence of pain was assessed and grouped into chronic and 
intermittent pain. This listing showed significant differences from an American 
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database study (NAPS2) on CP patients48, where a larger percentage of patients 
experienced pain, and the group of patients with constant pain far exceeded the group 
with intermittent pain. This difference could relate to different pain assessment 
methods, ethnic differences, differences in disease stage, and differences in alcohol 
and tobacco consumption, as described in the article. The way pain is registered in the 
database could also be of interest when assessing the difference's cause. In the SBPC 
database, patients treated with analgesics and reported no pain were registered as 
being pain-free. While this is a factual truth, the cause for analgesic treatment 
prescription is not explored, and this could hide a large group of patients with chronic 
pain that is well-treated with analgesic agents. 
Database studies are favorable, as the data is collected continuously without any 
inconvenience to the participant. The patient's behavior is typically not affected by the 
awareness of being studied, as the process is continuously and typically following an 
outpatient follow-up regime144. However, it does not leave room for an extended 
gathering of information, e.g., if additional health information is required, it is often 
not accessible due to the anonymization of data, which poses a limitation. 
 
6.1.3. QST STUDIES 
Objective assessment of pain is desirable yet hardly obtainable due to the subjective 
nature of pain sensation. According to Melzack et al., perceived pain comprises 
several dimensions, including sensory, affective, and evaluative25. To separate the 
sensory dimension from the other dimensions is likely impossible, and pain intensity 
estimation comes with accepting subjective influence. 
QST paradigms have evolved significantly over time. Earlier batteries included 
complex visceral stimulations and several different stimulation types. This provided 
detailed information but was also quite time-consuming and not possible to include in 
the clinic107,145. Therefore, a simplified paradigm, the NASQ paradigm, was 
developed, which is the paradigm used in study II. This paradigm only involved 
somatic stimulations, making it better tolerated by patients, and included an evaluation 
of CPM and pain thresholds by pressure and electrical stimulations131. Table 1 





PAIN IN PATIENTS WITH CHRONIC PANCREATITIS 
54
 
Studies QST stimulations References 
Treatment studies 
 Pregabalin Somatic pressure stimulation, somatic electrical stimulations, cold-pressor 
test, visceral electrical stimulation 
[33,83, 
117,145] 
 Ketamine Somatic pressure stimulation [147] 
 Opioids Pinch stimulation, somatic heat stimulation, transcutaneous electrical 
stimulation, somatic pressure stimulation, somatic electrical stimulation, 
visceral mechanical stimulation, visceral electrical stimulation, and 
visceral thermal stimulation 
[148] 
 Pancreatic duct 
decompression/pancreatic 
resection 
Electrical stimulation, cold-pressor test [149] 
 Thorascopic splanchnic 
denervation 
Somatic pressure stimulation, somatic electrical stimulation [150,151] 
 Electrical accentuation of vagal 
tone 
Somatic pressure stimulation, cold-pressor test [152] 
Examination of pain processing 
 Organization and connectivity 
of brain networks 
Contact heat-evoked potentials, electrical stimulation of the oeosophagus, 
stomach, and duodenum 
[53,153,154] 
 Comparison of pain responses 
with healthy volunteers 
Pinch stimulation, heat stimulation, transcutaneous electrical stimulation, 
somatic pressure stimulation, somatic electrical stimulation, repetitive 
pinprick stimulation, cold-pressor test, visceral mechanical stimulation, 




 Examining QST phenotypes of 
CP patients  
Somatic pressure stimulation, repetitive pinprick stimulations, cold-
pressor test 
[156] 
 Association between 
sympathetic activity and 
hyperalgesia  
Somatic pressure stimulation [157] 
Reliability of QST measurements in CP patients 
 Reliability of static and 
dynamic stimulations 




Table 1. A review of previously performed QST studies in CP patients. 
 
Unfortunately, an examination of temporal summation was not included in the NASQ 
paradigm. After 71 patients had been completed, an examination of temporal 
summation was included in the protocol. As an effect of the late addition, the final 
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data was too incomplete to include this part in the analysis. This is a disadvantage 
when using data from several studies; not all registrations will be complete, which 
will weaken the ability to examine all subjects of interest. However, the advantages 
of extracting as much knowledge from data already collected as possible outweigh the 
disadvantages, as it minimizes patient discomfort and enhances the outcome gained 
from the time patients use when participating in clinical studies.  
In our study by Phillips et al.56, an algorithm for phenotyping central pain processing 
based on normative criteria for a P-QST paradigm was proposed. The P-QST 
paradigm was designed to simplify the NASQ paradigm further, aiming to create a 
paradigm that provides the information needed from an as simple as possible bedside 
examination. This algorithm included 1) CPM capacity, 2) cold pressor endurance 
time, 3) the sum of pPDT, and 4) temporal summation of the forearm and abdomen 
as markers of generalized, widespread sensitization and 5) a pPDT index (an index 
between the mean value of the pancreatic dermatome (ventral and back) and the mean 
value of the three other examination sites) and 6) temporal summation of the abdomen 
as markers of segmental sensitization56. This paradigm can be the basis for the 
diagnosis of sensitization and can prove valuable in future treatment response studies 
and treatment algorithms. In another study, we showed that this paradigm could 
differentiate CP patients into distinct phenotypes that were not confounded by 
psychiatric comorbidity156. 
For future studies, a test for temporal summation should be included from the 
beginning to showcase a complete pain processing concept. 
The reproducibility of QST can also pose a limitation. In CPM paradigms, 
reproducibility has been an issue in previous studies, especially when examining 
chronic pain patients114,132,158. These problems can be caused by several things, 
including fluctuating pain levels and generalized hyperalgesia132. Furthermore, the 
CPM paradigm consists of both pre- and post-conditioning stimulation thresholds, and 
these are subject to their own variability, as described by Olesen et al.132. In some 
studies, CPM capacity has been shown to predict treatment response35,86, and other 
studies have shown that specific treatments can change the CPM capacity 
significantly119,120. Likewise, many different pain conditions have been shown to have 
deficient pain modulation54,118,159 and taken together with the link to treatment 
response, it is a mechanism that needs to be examined when evaluating pain 
processing, despite the reproducibility issues. Different CPM regimens have proven 
to have better reproducibility, and the CPM paradigm can be optimized to improve 
reproducibility. Studies have shown that tourniquet cuff as the conditioning stimulus 
and pressure pain threshold as the test stimulus (preferable computer-controlled) has 
the highest reproducibility160,161. However, the reproducibility is often merely 
examined by estimating the ICC, and although this is the classical evaluation method, 
it is probably getting outdated, as more recent research focuses on Bland Altman plot 
analysis as a more reliable measure of reproducibility162. 
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6.1.4. QUESTIONNAIRE DEVELOPMENT 
Comparison of clinical trials typically limited the use of heterogeneous outcome 
measures, affecting the quality of meta-analyses. The OMERACT (Outcome 
Measures in Rheumatology) is an international initiative developed to improve the 
outcome measures in rheumatology by developing “core domains” to include in pain 
assessment163. The OMERACT initiative emphasizes the importance of validity 
(truth), reliability (discrimination), and feasibility as basic features essential for all 
outcome measures. Afterward, projects such as the “Initiative on Methods, 
Measurement, and Pain Assessment in Clinical Trials” (IMMPACT)30 and 
“Validation and Application of a patient-relevant core set of outcome domains to 
assess multimodal PAIN therapy” (VAPAIN)164 followed. The IMMPACT 
recommendations were developed by a group representing academia, governmental 
agencies, and pharmaceutical agencies and defined six core domains that should be 
applied to pain assessment in clinical studies regardless of etiology. The domains 
included pain assessment, physical functioning, emotional functioning, global 
improvement evaluation, symptoms and adverse effects if treatments are involved, 
and patient disposition30. The VAPAIN consensus statement was developed by a 
multi-professional panel, including patient representatives, pain physicians, 
physiotherapists, psychologists, and researchers. It resulted in 8 core domains, 
including pain intensity, pain frequency, physical activity, emotional wellbeing, 
satisfaction with social roles and activities, productivity, health-related quality of life, 
and patient’s perception of treatment goal achievement164. The use of any of these 
recommendations will increase pain evaluation's homogeneity and improve clinical 
studies' comparability. 
As no pain questionnaire has been developed explicitly for CP and validated 
sufficiently in the patient group, many different questionnaires have been used in 
clinical studies. This makes the pain evaluation heterogeneous and complicates the 
















Pain assessment tools No. of studies No. of RCT’s References 
One-dimensional    
 Visual Analogue Scale (VAS) 53 21 [165] 
 Numerical Rating Scale (NRS) 9 2 [166] 
 Pain improvement groups 5 1 [167] 
 Pain intensity groups 16 7 [168] 
 Pain pattern 12 2 [169] 
 Frequency of pain attacks 10 4 [170] 
 Post-prandial pain 5 3 [171] 
Two-dimensional    
 (No. of days with pain) x (median pain VAS) 1 1 [172] 
 (Daily pain duration) x (median pain VAS) 1 1 [173] 
 (Degree of frequency) x (median pain VAS) 1 0 [174] 
 (Pain frequency) x (pain severity) 1 0 [175] 
 (No. of hours of pain) x (median pain VAS) 1 1 [176] 
Multi-dimensional    
 McGill Pain Questionnaire 5 3 [166] 
 PainDetect Questionnaire 1 1 [126] 
 Pain score (based on scores of intensity, frequency, and 
pain consequences) 
1 0 [177] 
Impact of pain    
 Quality of life scales 19 5 [178–180] 
 Brief Pain Inventory (BPI) 2 1 [126] 
 Pain Coping and Cognition List (PCCL) Questionnaire 1 0 [178] 
 Pain Disability Index (PDI) 2 1 [181] 
 
Table 2. Pain assessment tools used in clinical studies in CP patients. References 
indicate the first time the tool was used in an intervention study94. 
 
Study III and IV concerned developing a short form of the COMPAT questionnaire 
and testing for validity and reliability. The COMPAT questionnaire was primarily 
developed in New Zealand in English101, and therefore a translation of the study had 
to be established to collect data from patients from Aalborg. Translations introduce 
the risk of misinterpretations and changes in the meaning of the wording182. Although 
many Danish citizens speak English decently, details can be lost when it is not the 
participants’ mother tongue. This study's patient group often consists of socially 
vulnerable persons with less educational level than the general population's average 
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educational level183. These problems could also lead to misinterpretations and result 
in incomplete answers or answers of inferior quality. The questionnaire's 
interpretation was performed meticulously with contact with the original authors, if in 
doubt, to enhance the interpretation's quality. A native Danish speaker performed a 
back-translation, which is a limitation, as it would be optimal to have a native English 
speaking translator doing the translation. However, as our translator had an IELTS 
score of 8.5, which simulates that of a person with very good knowledge of the English 
language, it was deemed sufficient and did not significantly lower the translation 
quality. No significant differences were found between the translation and the original 
questionnaire, and it was evaluated that the language did not lose linguistics in the 
translation. The Danish patient group's answers were also compared with those of the 
New Zealandic patient group (see appendix A), and the only significant difference 
between the two groups concerned the rating of the word tender in the McGill-
questionnaire part of the COMPAT-SF. This difference is probably cultural, as the 
McGill questionnaire translation previously has been validated. 
Developing short forms of questionnaires is a task that needs to be evaluated 
thoroughly. It needs to capture the essence of the original questionnaire without losing 
too much depth. Usually, the short form items are chosen based on item response 
theory, item-total correlations, or factor analysis184. Nevertheless, many of these 
methods were not usable in the COMPAT questionnaire due to 1) a complex structure 
involving parts that only subgroups should answer and 2) the original questionnaire's 
comprehensiveness. The results are, however, controlled by confirmatory factor 
analysis, which endorsed the remaining items. As the original COMPAT 
questionnaire is not yet validated, the COMPAT-SF questionnaire was treated as a 
separate questionnaire that could withstand validation against other frequently used 
pain questionnaires. This validation gives the questionnaire independent value but 
does not prove that the results can compare to the original questionnaire results, and 
this must be done in future studies, preferably when a scoring system for the original 
questionnaire has been established. 
The validation process included three out of four commonly used validation methods. 
Face validation evaluates whether the questionnaire seems to capture the subject in 
focus and is done by non-experts in methodologies. This type of validation was 
omitted in the present study, as its value has been disputed96. Instead, the questionnaire 
was validated on content, construct, and criterion. 
 
6.2. CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
This thesis is focused on the characterization of pain and pain-related risk factors in 
patients with CP. It gives us an exhaustive knowledge of how the patients experience 
pancreatic pain and how pain mechanisms are affected by chronic pain.  
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As there now is a pain questionnaire explicitly developed for CP patients and validated 
against previously used questionnaires, as well as clinical factors such as quality of 
life and hospitalization burden, this could be incorporated into the monitoring of CP, 
and specific attention could be directed to those who scores above average and might 
be insufficiently treated. The long evaluation period in the COMPAT-SF 
questionnaire can complicate the use in clinical research. In treatment studies, the 
evaluated time-span can pose a bias to detect treatment effect during shorter treatment 
regimens. This must be addressed by considering a change to the evaluated period to 
accommodate the individual study. 
The characterization of risk factors for pain in CP can prove valuable when assessing 
which interventions could help manage CP, including non-pharmacological 
interventions. Smoking and alcohol cessation has been known to be substantial risk 
factors for developing CP48,185. However, study I shows that the current abuse is also 
essential for the present pain profile and intensity, and this could be used as an 
educational tool when introducing the importance of abstaining from alcohol and 
tobacco to the individual patient. 
QST examinations can prove valuable when assessing pancreatic pain. It can indicate 
which patients could benefit from invasive treatment such as surgery or endoscopy 
and which would be more inclined to respond to medical treatment105. The Mech 
Sense research group is currently working on a study implicating QST results in 
predicting response to endoscopic treatment. It is hypothesized that patients with signs 
of central sensitization have significant changes in their central nervous system and 
would, on that behalf, not benefit from local treatment. If this proves to be the point, 
it would be able to spare patients from enduring endoscopies that do not improve their 
pain status and limit those for patients where the chance of clinical improvement is 
probable. 
If surgery is deemed inefficacious, the QST results can potentially also be used to 
choose medical treatment and predict treatment response. This thesis opens to the 
possibility of creating and validating treatment algorithms, such as the one proposed 
in paper I. The thesis lays the basis for such an algorithm as it is impossible to build 
an algorithm without the tools necessary to form an in-depth characterization of pain. 
It should also include assessing the psycho-social aspects of pain, such as depression, 
catastrophizing thoughts, sleep, and sexual function186. The COMPAT-SF is an 
essential tool in estimating pain intensity and pain characteristics that affect patients' 
quality of life. However, several vital aspects of pain have not been included in this 
questionnaire, such as anxiety, depression, sleep disturbances, and sexual 
disturbances. These are universal aspects similar in all chronic pain conditions and 
can be assessed through previously validated questionnaires. 
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Further studies on QST-based prediction of treatment response could improve an 
algorithm's outcome, and the algorithm must be kept up to date as new research 
emerges. 
If a treatment algorithm is proved effective, it opens the door to scaling the knowledge 
beyond CP onto the general chronic pain patient. QST guided treatment in patients 
with central sensitization could be easily transferable, as the mechanisms causing 
central sensitization are likely, not disease-specific but generally the same despite the 
origin of pain73. This is currently being examined in the validation of the full 
COMPAT questionnaire, where answers from patients with other types of chronic 
pain are compared with answers from CP patients, and preliminary data indicate that 
those who show signs of being centrally sensitized are comparable between the two 
groups, whereas the others are not.  
However, to use an algorithm developed for CP patients for other chronic pain 
patients, characterization must be adjusted to fit the individual pain condition, 
focusing on disease-specific complications, questionnaires validated for the patient 
group in question, and segmental QST measurements targeted on affected 
dermatomes. 
This could lay the groundwork for changing pain treatment in chronic pain patients. 
However, it calls for validation of the algorithm, which is a difficult study to perform, 
as randomization can only be done at center-level, due to knowledge of the algorithm 
possibly could bias the choice of analgesic treatment in the standard-care group if the 




CHAPTER 7. CONCLUSION 
This Ph.D. thesis aimed to identify clinical risk factors of pain in patients with CP and 
characterize pancreatic pain thoroughly and comprehensively through QST and a pain 
questionnaire. Based on the six objectives, we concluded that pancreatic pain is a 
frequent symptom in CP and is challenging to manage, as many factors need to be 
considered in the choice of treatment. Concurrent, modifiable risk factors for 
pancreatic pain include smoking, very heavy alcohol abuse, pseudocysts, and 
duodenal stenosis. A trend towards constant pain was shown in moderate to marked 
pancreatic duct changes. 
The remaining aims focused on pain characterization as a primary step towards 
individualization of pain management. We concluded that pathophysiological pain 
processing mechanisms in patients with CP could be characterized using QST. The 
QST examinations in study II showed significant differences between patients and 
healthy controls, and some of the differences were associated with clinical pain 
intensity and interference scores, underlining the clinical importance of defective pain 
processing.  
Furthermore, a brief pain assessment questionnaire was developed explicitly for 
patients with CP, and it proved to be both valid and reliable. These two measures 
(QST and the COMPAT-SF questionnaire) comprise a reasonable basis for pancreatic 
pain characterization. They can be combined with additional assessment tools, 
including depression and anxiety scales, sleep evaluation, pain catastrophizing scales, 
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Appendix A. COMPAT-SF results 
This table compares the answers of the COMPAT-SF questionnaire from Danish and 
New Zealandic patients, respectively. The comparison is performed as student t-tests, 
Mann-Whitney U test, or Chi-square test as appropriate. Due to multiple comparisons, 
the results are Bonferroni corrected with a significance value of 0.5/42 = 0.0012. 
Significant values are marked in bold. 
  Denmark New 
Zealand 
p-value 
Pattern A 34% 43% 0.0110 
B 16% 5% 
C 29% 50 
D 21% 2% 
Pain intensity Average 5.3 5.7 0.3912 
Worst 7.9 7.6 0.6284 
Least 4.1 3.3 0.5163 
Opioid use   39% 36% 0.8080 
Provoking 
factors 
Any food 2 2 1.0000 
Fatty food 2.2 2.5 0.3049 
Fluids 1.2 1.3 0.5850 
Alcohol 2.5 3.0 0.2247 
Stress 1.5 2.0 0.1296 
Cigarettes 1.7 2.8 0.0274 
Exercise 1.5 1.7 0.6085 
Socialising 1.4 1.2 0.6167 
Weather changes 1.0 0.9 0.9088 
Light touch on skin 1.1 1.0 0.7797 
Cold/heat on skin 0.9 1.0 0.8793 
Pressure on skin 1.4 1.3 0.8248 
Widespread pain Head 1.8 1.2 0.1046 
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Joint 2.3 1.7 0.2748 
Limbs 2.3 1.6 0.1876 
Back/neck 2.7 2.2 0.3122 
Abdominal/pelvic 1.7 1.5 0.7019 
Muscle 1.2 1.2 0.9372 
Chest 1.1 0.8 0.5855 
McGill Throbbing 2.1 3.4 0.0809 
Shooting 3.9 4.1 0.8447 
Stabbing 2.7 4.8 0.0204 
Sharp 5.5 5.8 0.7184 
Cramping 3.1 4.2 0.1970 
Gnawing 2.8 3.8 0.2634 
Hot-burning 2.4 3.2 0.3312 
Aching 1.9 4.3 0.0041 
Heavy 5.9 4.1 0.0619 
Tender 1.8 4.3 0.0005 
Splitting 0.7 2.7 0.0030 
Tiring-exhausting 4.2 5.8 0.0764 
Sickening 4.2 5.4 0.1725 
Fearful 5.7 3.6 0.0241 
Punishing-cruel 3.4 3.7 0.7386 
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